GeneDx Forecast, price target & analysts
GeneDx Target price 2025 - Analyst rating & recommendation
GeneDx Classifications & Recommendation:
GeneDx Price Target
| Target Price | $163.20 |
| Price | $136.09 |
| Potential |
19.92%
register free of charge
|
| Number of Estimates | 10 |
|
10 Analysts have issued a price target GeneDx 2026 .
The average GeneDx target price is $163.20.
This is
19.92%
register free of charge
$194.25
42.74%
register free of charge
$141.40
3.90%
register free of charge
|
|
| A rating was issued by 13 analysts: 11 Analysts recommend GeneDx to buy, 2 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the GeneDx stock has an average upside potential 2026 of
19.92%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2031
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 305.45 | 431.20 |
| 50.79% | 41.17% | |
| EBITDA Margin | -1.74% | 11.20% |
| 97.49% | 741.85% | |
| Net Margin | -17.12% | 9.34% |
| 80.27% | 154.56% |
10 Analysts have issued a sales forecast GeneDx 2025 . The average GeneDx sales estimate is
This results in the following potential growth metrics:
7 Analysts have issued an GeneDx EBITDA forecast 2025. The average GeneDx EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
10 GeneDx Analysts have issued a net profit forecast 2025. The average GeneDx net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2031
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -1.94 | 1.39 |
| 73.17% | 171.65% | |
| P/E | 97.64 |
10 Analysts have issued a GeneDx forecast for earnings per share. The average GeneDx EPS is
This results in the following potential growth metrics and future valuations:
Current GeneDx Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Canaccord Genuity |
Locked
➜
Locked
|
Locked | Dec 22 2025 |
| Wells Fargo |
Locked
➜
Locked
|
Locked | Dec 15 2025 |
| BTIG |
Locked
➜
Locked
|
Locked | Dec 12 2025 |
| Wells Fargo |
Locked
➜
Locked
|
Locked | Nov 04 2025 |
| BTIG |
Locked
➜
Locked
|
Locked | Oct 29 2025 |
| Guggenheim |
Locked
➜
Locked
|
Locked | Oct 29 2025 |
| Canaccord Genuity |
Locked
➜
Locked
|
Locked | Oct 29 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Canaccord Genuity:
Locked
➜
Locked
|
Dec 22 2025 |
|
Locked
Wells Fargo:
Locked
➜
Locked
|
Dec 15 2025 |
|
Locked
BTIG:
Locked
➜
Locked
|
Dec 12 2025 |
|
Locked
Wells Fargo:
Locked
➜
Locked
|
Nov 04 2025 |
|
Locked
BTIG:
Locked
➜
Locked
|
Oct 29 2025 |
|
Locked
Guggenheim:
Locked
➜
Locked
|
Oct 29 2025 |
|
Locked
Canaccord Genuity:
Locked
➜
Locked
|
Oct 29 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
